Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma

Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma

Background: Minimal residual disease (MRD) is an important prognostic factor for evaluating a deeper treatment response in patients with multiple myeloma (MM). We evaluated the clinical utility of next-generation flow (NGF)-based MRD assessment in a heterogeneous MM patient population. Methods: Pati...

Full description

Bibliographic Details
Main Authors: Cho, D. (Author), Kim, H.-J (Author), Kim, H.-Y (Author), Kim, K. (Author), Kim, S.-H (Author), Kim, S.J (Author), Lim, D.J (Author), Yoo, I.Y (Author), Yoon, S.E (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
Minimal residual disease
Multiple myeloma
Next-generation flow cytometry
Progression-free survival
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items